A single-center retrospective cohort study of Covid-19 medications: Remdesivir, Favipiravir, Methylprednisolone, Dexamethasone, and Interferon β1a and their combinations

  1. Sahand Tehrani Fateh
  2. Sepand Tehrani Fateh
  3. Esmaeil Salehi
  4. Nima Rezai
  5. Nazanin Haririan
  6. Abdollah Asgari
  7. Amir Salehi-Najafabadi

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

Many drugs have been suggested to be used for Covid-19. A suitable and efficient choice of drug would make the course of Covid-19 easier. we have investigated the efficacy of different treatment regimen in reducing hospitalization period (HP) and mortality of 324 confirmed Covid-19 patients. Received drugs included single therapy or combinations of Methylprednisolone, Remdesivir, Favipiravir, Interferon β1a, and Dexamethasone. HP and mortality were compared between different treatment groups to evaluate efficacy of each drug. HP and mortality were also calculated for patients in each treatment group based on their underlying diseases and age. we suggest that using IFN-β1a, RDV and corticosteroids might not have a significant effect on the HP or mortality of the Covid-19 patients as it was thought before.

Article activity feed

  1. ScreenIT

    SciScore for 10.1101/2021.03.05.21251351: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementConsent: Patients who received treatments were all informed and a consent is obtained.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    We did statistical analyses using R language (4.0.2 ed,2020) implemented in R studio (1.3.1093 ed,2020)10,11 and Microsoft Excel software.
    Microsoft Excel
    suggested: (Microsoft Excel, RRID:SCR_016137)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    After all, our study faces several limitations, including 1-Limited number of patients, 2-The existence of confounders that may not have been discovered, 3-The existence of a large variance between some parameters, 4-A slight difference in patients’ conditions in terms of severity of the disease, 5-Not considering the clinical course of the disease and the fact that some patients progress to a need for mechanical ventilation and 6-Rarely in some cases some drugs were not started from the beginning of the hospitalization.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  2. Version published to 10.1101/2021.03.05.21251351v1 on medRxiv